KINAXO Exit

KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare.

Exit since Feb. 2011. Purchaser: Evotec AG

Management

Dr. Andreas Jenne

Pressemeldungen

Evotec acquires Kinaxo, Profitable Exit for Seed-Investor High-Tech Gründerfonds

Evotec expands its drug discovery platform with cutting-edge technologies Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted…
Read

Info & Contact

Phone:
+49 89 452 44 65-0
Web:
www.kinaxo.de

Address

Am Klopferspitz 19a
82152 Martinsried

In portfolio

21. Jul 2006 – 09. Feb 2011
Exit